Product Reports Resources Pricing Login Book a demo

Cytek

Biotech & Life Sciences · Fremont, United States · Founded 1992 · IPO 2021

A leading manufacturer and supplier of flow cytometry products and services MoreLess

Cytek Biosciences is a cell analysis solutions company that provides instruments, software, and services to the life sciences sector. The company's core technology is its proprietary Full Spectrum Profiling™ (FSP™), which is integrated into its flow cytometry instruments. These systems are designed to provide high-resolution and high-content cell analysis, enabling researchers and clinicians to obtain deeper insights from a single sample.

The company's product portfolio includes the Aurora and Northern Lights systems, which are full spectrum flow cytometers, and the Cytek Aurora CS, a cell sorter. To support its hardware, Cytek offers software for panel design and data analysis, such as the SpectroFlo® software and the Cytek Cloud platform. Its business model revolves around the sale of these instruments and related reagents, as well as providing technical support and training services.

Cytek serves a global market, with customers in academic research institutions, pharmaceutical and biotechnology companies, and clinical research organizations. The company is focused on applications in immunology, oncology, and cell biology, aiming to advance research in these fields.

Keywords: cell analysis, flow cytometry, biotechnology, life sciences, medical devices, diagnostics, immunology, oncology, reagents, scientific instruments

Valuation $100–500M
Revenue $100–500M
EBITDA $88K
Headcount 100–500
Total funding $100–500M

Talent graph

Cytek's talent

Book a demo to see the people
Employees mapped 444 incl. 6 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 9 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Cytek's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Series B+ 6 investors entered at this stage
3E Bioventures
NLVC
Hillhouse Capital
RA Capital Management
LYFE Capital
OrbiMed

Global footprint

Where Cytek has talent and traffic

Workforce by country
23 countries with
team presence
🇺🇸 United States65.8%
🇨🇳 China5.7%
🇳🇱 Netherlands5.4%
🇩🇪 Germany3.9%
🇫🇷 France3.6%
Top 5 of 23 shown
Web traffic by country
79K monthly visits
across markets
🇺🇸 United States54.2%
🇨🇦 Canada5.2%
🏳️ Korea3.9%
🏳️ Republic of3.9%
🇩🇪 Germany3.2%
Top 5 markets shown

Patent intelligence

Cytek’s patent portfolio

Estimated portfolio value
$24M

116 active families in the valuation dataset.

Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.

Compare patent portfolios across companies →

Market sentiment

What the market is saying about Cytek

An AI-synthesized read of the highest-engagement posts about Cytek on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cytek on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.